氯吡格雷对ACS患者血浆Lp-PLA2\hs-CRP的影响(2)
 |
| 第1页 |
参见附件。
[2] Brilakis ES, McConnell JP, Lennon RJ, et al.Association of lipoprotein -associated phospholipase A2 levels with coronary artery disease risk factors,angiographic coronary artery disease,and major adverse events at follow-up.Eur Heart J,2005,26:137- 144.
[3] Caslake MJ, Packard CJ, Suckling KE, et al.Lipoprotein- associated phospholipase A2, platelet- activating factor acetylhydrolase:a potential new risk factor for coronary artery disease.Atherosclerosis,2000,150(2):413 - 419.
[4] Dada N, Kim NW, Wolfert RL.Lp-PLA2:an emerging biomarker of coronary heart disease.Expert Rev Mol Diagn,2002,2(1):17-22.
[5] Macphee CH, Lipoprotein- associated phospholipase A2:a potential new risk factor for coronary artery disease and a therapeutic target.Current Opinion in Pharmacology,2001,1(2):121-125.
[6] Tataru MC, Heirnish J, Junker, et al.C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable anginapectoris.Eur Heart J, 2002,21(12):1000 - 1008.
[7] Xiao Z,Theroux P.Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.J Am Con Cardiol,2004,43(11):1982-1988.
[8] 华先平,杜令,孔祥辉,等.氯吡格霄对兔动脉粥样硬化血清高敏C-反应蛋白和血管壁核因子-κΒ表达的影响.实用医学杂志,2007,23(1):25-27.
您现在查看是摘要介绍页，详见PDF附件。